Latest news with #PierreFabre
Yahoo
a day ago
- Business
- Yahoo
Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ
SECAUCUS, N.J., June 18, 2025 /PRNewswire/ -- Pierre Fabre Laboratories, a global healthcare company originated from France, announces the inauguration of its new US office located on 500 Plaza Drive, in Secaucus, NJ which will host its dermo-cosmetics and medical care subsidiaries. Pierre Fabre is the world's second-largest dermo-cosmetics manufacturer and a global player in oncology, cell & gene therapy, rare disease and dermatology. This strategic move in the US marks a pivotal moment in the company's growth strategy, underscoring its strong commitment to advancing in the US in both dermo-cosmetics and medical care. Pierre Fabre Laboratories introduced global dermo-cosmetics brands Avène, Klorane and René Furterer to the US market in the 1990's. With an ever-growing desire for French dermo-cosmetics, the US dermo-cosmetics business has become a top priority. Building upon their success in oncology and dermatology in Europe and Asia, the company has recently expanded its medical care investments in the US through the creation of a dedicated pharmaceutics unit, Pierre Fabre Pharmaceuticals (PFP). This subsidiary is focused on continuing to deliver breakthrough therapies in rare diseases and oncology to American patient populations with high unmet needs and limited treatment options. Eric Ducournau, CEO of Pierre Fabre Laboratories states, "we have declared the United States a priority geography for the company. The US is not only the biggest market in the world for pharmaceuticals and cosmetics alike, but also the most disruptive market for therapeutic innovation. For 15 years, we have built strategic partnerships with highly innovative US biotechnology companies in the fields of oncology, rare diseases, and medical dermatology. We have also multiplied by 10 times the turnover of our blockbuster brand Eau Thermale Avène since 2010, and its potential remains huge given the growing appetite of American consumers for cosmetics designed and tested with the same rigor as for medicines. We are now determined to walk the next step forward and the opening of our new office in Secaucus with plans to expand in the rare diseases and oncology business is a testimony to this dedication." Secaucus, NJ offers a strategic location with excellent transportation links to New York City and the broader tri-state area. Designed to represent the company's core values, the office showcases its deep respect for the environment, a commitment to sustainable innovation and allows for hands on learning through an onsite space that offers an immersive skin and hair care experience. This thoughtfully curated environment is engineered to spark creativity and foster teamwork across all departments. "This new office is more than just a space, it's a hub for collaboration, innovation, and showcases the team's hard work and dedication. It embodies the Group's commitment to pushing boundaries across both business units in derm-cosmetics and pharmaceutics, while providing New Ways to Care for all" said Lisa Morris, President and CEO of Pierre Fabre USA. "Today's office opening demonstrates the steadfast commitment of Pierre Fabre Laboratories to building a powerful presence for medical innovation and patient impact in the US," said Adriana Herrera, CEO of PFP. "Leveraging our strength as a humanitarian foundation owned company, PFP has been focused over the past 18-months on building the US Medical Care operations and to bring on board an experienced, agile and purpose driven US team focused on creating long-term value and hope for patients, by delivering innovative therapies to people living with cancer who are in urgent need of effective, life-extending treatment options." With this new footprint in the US, Pierre Fabre Laboratories is positioning itself for even greater impact with American patients and healthcare professionals in dermo-cosmetics and pharmaceuticals. For the company, this is only the beginning. For more information, visit or follow @aveneusa on Instagram Note: High-resolution images, interviews, and product samples are available upon request. ABOUT PIERRE FABRE LABORATORIES Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow, and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care, and family health care. In 2024, Pierre Fabre Laboratories posted 3.1 billion euros in revenues, 70% of which came from international sales in 120 countries. Based in southwest France since its creation and manufacturing nearly 90% of its products in France, Pierre Fabre Laboratories employs 10,200 people worldwide. Its R&D budget amounted to 220 million euros in 2024, of which 60% is allocated to targeted therapies in oncology and 35% to skin health and care solutions. Pierre Fabre Laboratories' majority shareholder (86%) is an eponymous humanitarian Foundation. Employees constitute the company's other shareholders. This capital structure guarantees the company's independence, long-term vision, and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world. Pierre Fabre Laboratories' CSR policy has been assessed by AFNOR Certification and has been awarded the "Exemplary" level of its CSR label (ISO 26 000 standard for sustainable development). For more information, visit Media Contact:Elena Suarez-Peñ View original content to download multimedia: SOURCE Avène USA
Yahoo
4 days ago
- Business
- Yahoo
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /PRNewswire/ -- Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of Scorpion Therapeutics, Inc., of the worldwide rights for PFL-721 and PFL-241 (formerly known as STX-721 and STX-241, respectively). Under the terms of the agreement, Pierre Fabre Laboratories will expand its previous agreement with Scorpion Therapeutics to hold the global rights for both assets and will be leading the clinical development of both programs. PFL-721 is a mutant-specific EGFR exon 20 and HER2 exon 20 inhibitor, soon to transition to dose optimization within a first-in-human trial in NSCLC. PFL-241 is a mutant-specific, brain penetrant, 4th generation EGFR inhibitor, currently in dose escalation in a first-in-human trial, to address C797S resistance mutations in NSCLC patients. NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in approximately 14-38 percent of tumors, depending on geography.[1], [2], [3] "With this agreement with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241. The R&D team is fully engaged and committed to progress the clinical development of these programs, aiming at providing novel and differentiated precision medicines to patient populations with significant unmet needs." said Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories. About Pierre Fabre Laboratories Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care. [1] The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer, Oncotarget, October 2016 [2] EGFR Mutation Incidence in Non-Small Cell Lung Cancer, J Cancer Res., August 2015 [3] Molecular Epidemiology of EGFR Mutations in Asian Patients, PLoS ONE, November 2015 PDF - Pierre Fabre Laboratories Media Contact: Laure Bregeon-Sgandurra, SOURCE Pierre Fabre Laboratories Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
